mRNA-Lipid Nanoparticle Vaccine Shows Promise Against Severe Allergic Reactions in Preclinical Study
核心洞察
Researchers at Cincinnati Children's and University of Pennsylvania developed an mRNA-lipid nanoparticle vaccine that successfully reduced allergic responses in mice, offering a potential alternative to traditional allergy shots.
The vaccine demonstrated significant reductions in inflammation markers, including decreased eosinophils, reduced inflammatory cytokines IL-4 and IL-13, and protection from lung hyper-responsiveness typical of asthma.
This approach could address the global allergy epidemic affecting nearly 30% of the population, with asthma alone causing approximately 250,000 deaths annually according to the World Health Organization.
A novel mRNA-based vaccine delivered via lipid nanoparticles has demonstrated promising results in preventing severe allergic reactions in preclinical studies, potentially offering a revolutionary approach to treating the global allergy epidemic. The research, led by experts at Cincinnati Children's Hospital and the University of Pennsylvania, was published September 23, 2025, in the Journal of Clinical Investigation.
Addressing a Global Health Crisis
Allergic diseases have reached epidemic proportions worldwide, affecting nearly 30% of the population. Asthma, a dangerous outcome of allergic reactions, causes about 250,000 deaths globally each year according to the World Health Organization. Food allergies now affect 10% of the population, while allergic diseases collectively send millions to emergency departments and intensive care units, driving widespread missed time from school and work.
"This publication reports exciting findings that we hope will lead to clinical trials and has potential as a revolutionary approach for allergy interventions and treatment," says Marc Rothenberg, MD, PhD, director of the Division of Allergy and Immunology at Cincinnati Children's.
Novel Vaccine Technology
The vaccine concept builds upon years of work led by Drew Weissman, MD, PhD, director of the Penn Institute for RNA Innovation at the University of Pennsylvania, who was awarded a Nobel Prize in 2023 for his contributions to mRNA technology that led to the first effective COVID vaccines.
The research team attached specific allergy-related mRNA strands to nanoparticles derived from lipids. Each nanoparticle measures approximately 50 nanometers across, meaning it would take about 2,000 of these particles to equal the width of a single human hair.
Promising Preclinical Results
After injection with the nanoparticle vaccine, mice were exposed to allergens that normally trigger various immunological and clinical responses typical of allergic reactions, including airway-swelling asthmatic responses.
The vaccinated mice showed remarkable improvements across multiple allergy markers:
- Reduced levels of inflammation, including decreased allergy-associated white blood cells (eosinophils)
- Reduction in inflammatory cytokine mediators critical in allergic responses, specifically Interleukin-4 and Interleukin-13
- Less mucus production in the lungs
- Protection from lung hyper-responsiveness typically seen in asthma
- Production of allergen-specific antibodies known to block allergic responses
"These findings identify a conserved immune mechanism across species, regardless of the mRNA-encoded protein. Allergen-specific mRNA-LNP therapy may be a promising approach for prevention and treatment of human allergic diseases," Weissman explains.
Advantages Over Current Treatments
This approach differs significantly from existing "allergy shot" regimens, which involve complex protocols focused on injecting purified allergens into patients. Experts in immunology contend that severe inflammatory reactions follow similar courses despite having differing initial triggers, suggesting that a single well-designed vaccine that can blunt inflammatory responses might be effective against multiple allergic diseases.
Currently, millions of people rely on various treatments including special diets, inhalers, and injections to manage their symptoms, along with difficult regimens to avoid allergy triggers.
Future Research Directions
"Our study demonstrates that mRNA-LNP therapy can reshape immune response to allergens, offering a powerful new tool for allergy treatment," says first author Yrina Rochman, PhD. "With further research, this platform has the potential to advance allergy care across diverse clinical settings and deepen our understanding of the mechanisms behind immunotherapy."
The key impact of this study is proof-of-concept that a more versatile vaccine approach exists for treating and preventing allergic disease. However, more research is needed to develop the vaccine for human use, including determining safety for people, how many types of allergens can be included in a single dose, and how long any increased protection might last.
The research represents a collaborative effort involving multiple institutions and facilities, with co-authors from Cincinnati Children's, the University of Pennsylvania, and Children's Hospital of Philadelphia contributing to this groundbreaking work.